Copy Link Print Information

Mirvetuximab

(Synonyms: M9346A)
2 Cited Publications
Customer Review

Based on 2 publication(s) in Google Scholar

Mirvetuximab (M9346A) is an anti-FOLR1 (folate receptor 1) monoclonal antibody. Mirvetuximab is the antibody moiety of folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research.

For research use only. We do not sell to patients.

  • Purity: 99.88%
  • CAS No.: 1453084-36-0
  • Molecular Weight:145.2 kDa
  • Storage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Experimental Validation Results for Mirvetuximab
  • Experimental Validation Results for Mirvetuximab
  • Experimental Validation Results for Mirvetuximab
  • Experimental Validation Results for Mirvetuximab
  • Experimental Validation Results for Mirvetuximab
  • Experimental Validation Results for Mirvetuximab
  • Experimental Validation Results for Mirvetuximab
  • Experimental Validation Results for Mirvetuximab
  • Experimental Validation Results for Mirvetuximab
  • Mirvetuximab Chemical Structure
    Mirvetuximab Chemical Structure
CAS No.: 1453084-36-0
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Mirvetuximab:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Purity & Documentation
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Mirvetuximab

More
Customer Validation & Images
In Vivo Efficacy StudyBio/Physico-chemical AssayHistological Imaging/StainingIn Vivo Imaging
  • Bio/Physico-chemical Assay
  • Bio/Physico-chemical Assay
  • In Vivo Imaging
  • In Vivo Efficacy Study
  • Histological Imaging/Staining
Keywords
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • 1/16

    Human IgG1 kappa

  • 1/16

    Flow cytometric analysis of 1X106 MCF-7 cells with Mirvetuximab (HY-P99225, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

  • 1/16

    Immobilized FOLR1 Protein, Human (HEK293, His) can bind Mirvetuximab. The EC50 for this effect is 6.576 ng/mL.

  • 1/16

    Flow Cytometry analysis of Raji cells labelling Siglec-2/CD22 (red) with Pinatuzumab (anti-Siglec-2/CD22) (HY-P99230). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.

  • 1/16

    Mirvetuximab purchased from MedChemExpress. Usage Cited in: Chem Biomed Imaging. 2025 Nov 17;XXXX(XXX).

    Customer Validation
     Binding affinity experiments of Zr-DFO-Mirvetuximab (2 h) to the FRα protein were performed.

  • 1/16

    Mirvetuximab purchased from MedChemExpress. Usage Cited in: Chem Biomed Imaging. 2025 Nov 17;XXXX(XXX).

    Customer Validation
     Cell uptake experiments were conducted with Zr-DFO-Mirvetuximab in CAL51 and MDA-MB-231 cells.

  • 1/16

    Mirvetuximab purchased from MedChemExpress. Usage Cited in: Chem Biomed Imaging. 2025 Nov 17;XXXX(XXX).

    Customer Validation
     Micro-PET/CT imaging of CAL51 and MDA-MB-231 tumor models was performed at 24, 72, 96, 120, and 144 h p.i.

  • 1/16

    Mirvetuximab purchased from MedChemExpress. Usage Cited in: bioRxiv. 2025 Oct 27:2025.10.27.684721. [Abstract]

    Customer Validation
     Relative tumor volume of Mirvetuximab (4.5 mg/kg at Day 0 and Day 7 (i.v)) was measured.

  • 1/16

    Mirvetuximab purchased from MedChemExpress. Usage Cited in: bioRxiv. 2025 Oct 27:2025.10.27.684721. [Abstract]

    Customer Validation
     Histological evaluation of tumor tissues at the study end point was performed by H&E (Magnification 10X (top panel) and 40X (bottom panel); Scale bar: 100µm). Mirvetuximab (4.5 mg/kg at Day 0 and Day 7 (i.v.)) was administered.

  • Mirvetuximab Chemical Structure
    1/16
  • Mirvetuximab
  • Flow cytometric analysis of 1X106 MCF-7 cells with Mirvetuximab (HY-P99225, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
  • Immobilized FOLR1 Protein, Human (HEK293, His) can bind Mirvetuximab. The EC50 for this effect is 6.576 ng/mL.
  • Flow Cytometry analysis of Raji cells labelling Siglec-2/CD22 (red) with Pinatuzumab (anti-Siglec-2/CD22) (HY-P99230). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.